Automate Your Wheel Strategy on NVO
With Tiblio's Option Bot, you can configure your own wheel strategy including NVO - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowNews
HIMS Earnings Ahead: Wegovy Offers Upside, Analysts Advise Caution
Published: May 05, 2025 by: Schwab Network
Sentiment: Neutral
"There's a sense of caution" heading into Hims & Hers (HIMS) earnings, says Caroline Woods. The telehealth company is up over 65% so far in 2025 but has fallen more than 40% off its February highs.
Read More
5 Drug/Biotech Stocks Likely to Outperform Q1 Earnings Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Let us look at some drug/biotech stocks, NVO, PCRX, RARE, ACAD and DNLI, which are poised to beat on first-quarter 2025 earnings.
Read More
Novo Nordisk: FDA Accepts New Drug Application for Oral Wegovy
Published: May 02, 2025 by: WSJ
Sentiment: Positive
The Bagsvaerd, Denmark, company said that if the application is approved, Wegovy would become the first oral formulation of a GLP-1 drug for chronic weight management.
Read More
U.S. FDA accepts Novo Nordisk's application for oral Wegovy
Published: May 02, 2025 by: Reuters
Sentiment: Positive
The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for the experimental once-daily oral version of its blockbuster weight-loss drug Wegovy, the Danish drugmaker said on Friday.
Read More
Why Is Novo Nordisk Stock Trading Higher On Friday?
Published: May 02, 2025 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S' NVO Canada unit on Thursday announced that Health Canada has accepted for review, under the Priority Review policy, its supplemental new drug submission (sNDS) for semaglutide 2.4 mg, a once-weekly therapy for people living with MASH (metabolic dysfunction-associated steatohepatitis).
Read More
Why Eli Lilly, Viking Therapeutics, and Novo Nordisk Stocks All Popped Friday
Published: May 02, 2025 by: The Motley Fool
Sentiment: Positive
Positive jobs news and positive rumors out of China are lifting stock markets today, as the U.S. Labor Department reports adjusted nonfarm payrolls grew by 177,000 jobs in April, and CNBC reports that China may be "evaluating the possibility of starting trade negotiations" that could abbreviate a trade war with the U.S.
Read More
Is Most-Watched Stock Novo Nordisk A/S (NVO) Worth Betting on Now?
Published: May 02, 2025 by: Zacks Investment Research
Sentiment: Positive
Novo Nordisk (NVO) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment
Published: May 01, 2025 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S NVO announced that CVS Health Inc's CVS CVS Caremark, a Pharmacy Benefit Manager (PBM), has decided that Wegovy (semaglutide) injection 2.4 mg will soon be the preferred GLP-1 medicine on its largest commercial template formularies.
Read More
Why Novo Nordisk Stock Popped Today
Published: May 01, 2025 by: The Motley Fool
Sentiment: Positive
Novo Nordisk (NVO 0.33%) stock jumped 3.1% at the open Thursday morning before drifting back. As of 10:54 a.m.
Read More
CVS to boost access to Novo Nordisk's weight loss treatment Wegovy for patients on its drug plans
Published: May 01, 2025 by: CNBC
Sentiment: Positive
CVS Health said it will significantly expand access to the blockbuster weight loss drug Wegovy for patients covered by its pharmacy benefit manager, Caremark. Under a new partnership between Caremark and Wegovy's manufacturer, Novo Nordisk, CVS will make the drug available to its members at "a more affordable price.
Read More
Novo Nordisk: The Fear Is Overblown
Published: May 01, 2025 by: Seeking Alpha
Sentiment: Negative
Novo Nordisk's about 55% stock decline since June 2024 is driven by clinical trial misses, increasing competition, and geopolitical turbulence. Due to the compressed valuation, Novo Nordisk needs to grow in the mid-single digit range to justify the current valuation. Considering realistic growth rates, the company could be undervalued by 50+%.
Read More
Hims & Hers stock price soars after partnership with Novo Nordisk to offer weight-loss drug Wegovy
Published: April 30, 2025 by: Fast Company
Sentiment: Positive
Shares in Hims & Hers Health, Inc. (NYSE: HIMS) are skyrocketing in early-morning trading today after the telehealth company announced a new partnership with the Danish pharmaceutical giant Novo Nordisk. That partnership will see Hims & Hers offer Novo Nordisk's weight-loss drug Wegovy through its platform.
Read More
Why New Wegovy Deals Won't Restore Novo Nordisk's Obesity Lead
Published: April 30, 2025 by: WSJ
Sentiment: Negative
The Danish drugmaker is expanding Wegovy access via telehealth providers like Hims and Ro. But the gap with Eli Lilly is only getting wider.
Read More
Growth Is Priced Out Of Novo Nordisk
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Negative
A lot went wrong for Novo Nordisk A/S in the last six months, and a lot went right for competitor Eli Lilly. Novo Nordisk's competitive positioning in the obesity market has worsened, but I believe the market has overshot to the downside. Not all is lost, and there are additional efforts the company is making to stay relevant, ranging from new trials of CagriSema and higher doses of semaglutide, to external innovation.
Read More
Hims & Hers stock pops on Novo Nordisk partnership
Published: April 29, 2025 by: Proactive Investors
Sentiment: Positive
Hims & Hers (NYSE:HIMS) shares surged after it announced a partnership with Novo Nordisk that will allow it to offer the drugmaker's weight loss product Wegovy through its telehealth platform. Investors welcomed the collaboration, which positions Hims & Hers to participate directly in the fast-growing market for GLP-1 weight-loss drugs.
Read More
Hims & Hers Stock Surges As It Collaborates With Novo Nordisk To Sell Weight Loss Drug Wegovy On Its Platform
Published: April 29, 2025 by: Benzinga
Sentiment: Positive
Novo Nordisk A/S NVO and Hims & Hers Health, Inc. HIMS announced a long-term collaboration on Tuesday.
Read More
Pharma firms maastraz
Published: April 29, 2025 by: CNBC International TV
Sentiment: Neutral
Jimmy Muchechetere, senior equity analyst at Investec, weighs in on the prospect of pharmaceutical tariffs and recent U.S. investment commitments from the sector.
Read More
Novo Nordisk Before Q1 Earnings: How Should Investors Play the Stock?
Published: April 29, 2025 by: Zacks Investment Research
Sentiment: Neutral
NVO's first-quarter revenues are expected to have been driven by its sales of diabetes and obesity care products, especially Wegovy, Ozempic and Rybelsus.
Read More
Hims & Hers partners with Novo Nordisk to sell Wegovy
Published: April 29, 2025 by: Fox Business
Sentiment: Positive
Hims & Hers on Tuesday announced a collaboration with drugmaker Novo Nordisk to bundle Wegovy and a Hims & Hers membership on its telehealth platform.
Read More
Wegovy Today, Ozempic Tomorrow: Partnership With Novo Is Hims & Hers Comeback
Published: April 29, 2025 by: Seeking Alpha
Sentiment: Positive
Hims & Hers Health, Inc. just announced a partnership with Novo Nordisk, Ro and LifeMD to sell their Wegovy at a discounted price. The deal is a game changer, enabling Hims to offer Wegovy at $599/month versus $1,999/month. I think this deal hints at potential to do the same with Ozempic further boosting the stock, which is already up +30% in pre-market trading.
Read More
White House Slams AMZN, HIMS & NVO Wegovy Partnership, SOFI Rallies
Published: April 29, 2025 by: Schwab Network
Sentiment: Negative
Amazon (AMZN) shares faced selling pressure after the White House called the company's decision to display tariff costs on products a "hostile and political act." Diane King Hall notes it's just the latest company following a formula.
Read More
Hims & Hers to Sell Novo Nordisk's Wegovy in U.S., Shares Soar
Published: April 29, 2025 by: WSJ
Sentiment: Positive
Him & Hers Health and Novo Nordisk are collaborating to offer weight-loss treatment, including access to Wegovy along with other services to treat obesity.
Read More
Novo Nordisk's obesity drug Wegovy debuts in Thailand
Published: April 28, 2025 by: Reuters
Sentiment: Positive
Novo Nordisk has launched its hugely popular weight-loss drug Wegovy in Thailand, an executive of the Danish drugmaker's local subsidiary said on Monday, marking the injectable drug's first entry into the Southeast Asian market.
Read More
Why Novo Nordisk Stock Dropped Today
Published: April 25, 2025 by: The Motley Fool
Sentiment: Negative
Novo Nordisk (NVO -1.68%), the Danish drugmaker of GLP-1 weight loss drugs Ozempic and Wegovy, slipped 2% through 10:30 a.m. ET Friday after suffering a one-two punch from Reuters and a bank analyst.
Read More
Why Novo Nordisk Stock Popped Today
Published: April 22, 2025 by: The Motley Fool
Sentiment: Positive
Novo Nordisk (NVO 2.71%), the Danish drugmaker that's been riding high ever since it began putting out Ozempic and Wegovy GLP-1 injectables for treatment of diabetes and weight loss, got another shot in the arm yesterday -- one that helped the stock dodge the market downturn entirely and end the day somewhat in the green. The same news that helped Novo stock out yesterday, moreover, is today turning into solid gains as Novo Nordisk stock rises 2.5% through 11 a.m.
Read More
Novo Nordisk: Be Greedy When Others Are Fearful
Published: April 22, 2025 by: Seeking Alpha
Sentiment: Positive
Novo Nordisk is a high-quality biopharma company with a strong diabetes franchise and a booming obesity drug segment, making it an attractive growth play. Following a 50% drop from recent highs, NVO trades at a significant discount compared to historical valuations, presenting a buying opportunity. The company's diverse portfolio, including diabetes, obesity, and rare diseases, ensures robust growth and reduces reliance on any single product.
Read More
Think It's Too Late to Buy Novo Nordisk? Here's the Biggest Reason Why There's Still Time.
Published: April 22, 2025 by: The Motley Fool
Sentiment: Positive
Almost unarguably, the most significant story in our time with the pharmaceutical industry is the emergence and sharp rise of GLP-1 obesity drugs. Front and center of this is Novo Nordisk (NVO 0.48%), the once-obscure Danish company that earned the first U.S. Food and Drug Administration (FDA) approval for such treatments with its Wegovy back in mid-2021.
Read More
Novo Nordisk Shares Fall After Data From New Eli Lilly Pill
Published: April 22, 2025 by: WSJ
Sentiment: Negative
Shares fell after Eli Lilly announced results of a new pill that could rival the weight-loss potential of the Danish giant's blockbuster shots.
Read More
Down 60%, Is This Growth Stock Too Cheap to Ignore?
Published: April 22, 2025 by: The Motley Fool
Sentiment: Positive
In this video, I will cover recent updates regarding Novo Nordisk (NVO 0.48%). Watch the short video to learn more, consider subscribing, and click the special offer link below.
Read More
Is Novo Nordisk falling behind Eli Lilly in the weight-loss drug race?
Published: April 22, 2025 by: Invezz
Sentiment: Neutral
Danish drugmaker Novo Nordisk A/S (CPH: NOVO-B) lost more than 10% last week after its US rival Eli Lilly & Co (NYSE: LLY) reported encouraging Phase 3 data for its oral weight-loss treatment. Lilly's orforglipron demonstrated “statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines” in the late-stage clinical trial.
Read More
About Novo Nordisk A/S (NVO)
- IPO Date 1981-04-30
- Website https://www.novonordisk.com
- Industry Drug Manufacturers - General
- CEO Maziar Mike Doustdar
- Employees 77406